## PM: Philip Morris International Inc. - XLP: Consumer Defensive

### Executive Summary

VALUE thesis: PEG 1.05 indicates fundamental undervaluation. Quality metrics strong (ROA 15%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-6.9% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($140.85)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 1)

**1. Philip Morris International Expands its Partnership with Scuderia Ferrari HP, Launching a Bold New Chapter in Their Long-Standing Relationship**
- Source: Business Wire | 20251203T145141 | Bullish | Relevance: 100%
- Philip Morris International (PMI) announced an expanded partnership with Scuderia Ferrari HP and Ferrari Challenge Trofeo Pirelli, introducing its ZYN nicotine pouch brand to Scuderia Ferrari HP Formula 1 liveries at select races, starting with the Abu Dhabi Grand Prix 2025. This collaboration, spanning over five decades, reinforces innovation and shared values, aiming to accelerate the replacement of cigarettes. PMI emphasizes responsible marketing, targeting adult consumers with smoke-free alternatives, and highlights ZYN's global leadership and FDA authorization in the U.S.

**2. FERRARI RENEWS ITS PARTNERSHIP WITH PHILIP MORRIS INTERNATIONAL**
- Source: Markets Financial Content | 20251203T061900 | Somewhat-Bullish | Relevance: 100%
- Ferrari N.V. announced the renewal and strengthening of its multi-year partnership with Philip Morris International. Starting January 1, 2026, Philip Morris International will become a Premium Partner of Scuderia Ferrari HP and a Series Partner of the Ferrari Challenge Trofeo Pirelli, continuing a collaboration that has spanned over 50 years.

**3. Epoch Investment Partners Inc. Lowers Stake in Philip Morris International Inc. $PM**
- Source: MarketBeat | 20251205T101221 | Somewhat-Bullish | Relevance: 100%
- Epoch Investment Partners Inc. reduced its stake in Philip Morris International Inc. by 24.2% in the second quarter, selling nearly 200,000 shares. Despite this, other institutional investors have either increased or initiated positions in the company. Philip Morris International also recently increased its quarterly dividend and is currently rated as a "Moderate Buy" by analysts.

**4. Trek Financial LLC Purchases 37,683 Shares of Philip Morris International Inc. $PM**
- Source: MarketBeat | 20251204T140026 | Somewhat-Bullish | Relevance: 100%
- Trek Financial LLC significantly increased its stake in Philip Morris International (NYSE:PM) by over 732% in the second quarter, now holding 42,829 shares valued at approximately $7.80 million. This comes as Wall Street maintains a "Moderate Buy" consensus with an average target price of $189. The company also recently raised its quarterly dividend to $1.47, resulting in a 3.8% yield.

**5. Philip Morris International Inc. $PM Position Decreased by Triavera Capital LLC**
- Source: MarketBeat | 20251204T135926 | Neutral | Relevance: 100%
- Triavera Capital LLC reduced its holdings in Philip Morris International Inc. by 15.7% in the second quarter, selling 12,283 shares and ending with 65,794 shares valued at $11.98 million. The stock represents 6.3% of Triavera's portfolio and is its 7th largest holding. Analysts currently rate PM as a "Moderate Buy" with an average price target of $189.00, despite some recent price target trim by firms like Barclays and UBS, and the company recently increased its quarterly dividend to $1.47, resulting in a 3.8% yield and a payout ratio of 106.52%.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | JP Morgan | $185 | $190 | -3% |
| 2025-11-17 | Barclays | $180 | $220 | -18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | JP Morgan | main | Overweight |
| 2025-11-17 | Barclays | main | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 1 |

**Top Holders:**
- Vanguard Group Inc: 9.2% (+0.4%)
- Capital World Invest: 8.3% (+2.1%)
- Blackrock Inc.: 6.8% (+1.6%)
- JPMORGAN CHASE & CO: 6.1% (+105.8%)
- Capital Internationa: 5.7% (+1.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-6.9% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 9.9% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.05 suggests fair value with growth premium. Quality metrics strong (ROA 15%, margin 22%). Balance sheet: $4.1B free cash flow. Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (9 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $250.7B |
| Beta | 0.44 |
| 52W Range | $116.12 - $186.69 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.05 |
| Forward P/E | 17.7 |
| Current P/E | 19.6 |
| YoY Growth | 10.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.4% to -6.5% (-6.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 10.5pp (needs >4.0% for momentum thesis). AM_20 at -4.3% indicates price below own 20MA trend. Underperforming sector by 5.1pp, stock-specific weakness. Below SMA200 (0.90x), long-term trend not supportive. MACD histogram bearish (-0.63), momentum weakening. OFD pattern: -SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -6.46% (CS: 6) | Weak |
| RSI_14 | 38.1 | Neutral |
| MACD Histogram | -0.63 | Bearish |
| vs SMA20 | 0.957x | Below |
| vs SMA50 | 0.956x | Below |
| vs SMA200 | 0.901x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $147.81
- **Stop Loss:** $140.85 (4.7% risk)
- **Target:** $161.73 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 71
- **Position Value:** $10,494.51
- **Portfolio %:** 10.49%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-05 (Est: $1.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.10 | $2.24 | +6.9% |
| 2025Q2 | $1.86 | $1.91 | +2.8% |
| 2025Q1 | $1.61 | $1.69 | +4.8% |
| 2024Q4 | $1.50 | $1.55 | +3.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*